Cronograma de promoção Soleno Therapeutics, Inc.
Agenda avançada
Gráfico simples
Sobre a empresa Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.| IPO date | 2014-11-13 |
|---|---|
| ISIN | US8342033094 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://soleno.life |
| Цена ао | 49.03 |
| Alteração de preço por dia: | +0.6323% (49.03) |
|---|---|
| Alteração de preço por semana: | +10.18% (44.78) |
| Alteração de preço por mês: | -1.81% (50.25) |
| Alteração de preço em 3 meses: | +5.63% (46.71) |
| Mudança de preço em seis meses: | -6.54% (52.79) |
| Mudança de preço por ano: | +13.53% (43.46) |
| Mudança de preço em 3 anos: | +16 631.1% (0.2949) |
| Mudança de preço em 5 anos: | +1 604.55% (2.8946) |
| Mudança de preço em 10 anos: | 0% (49.34) |
| Mudança de preço desde o início do ano: | +9.21% (45.18) |
|
|
Subestimação
|
Eficiência
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Obrigação
|
Impulso de crescimento
|
|||||||||||||||||||||||||||||||||||||
| Instituições | Volume | Compartilhar, % |
|---|---|---|
| Vivo Capital, LLC | 8418093 | 25.93 |
| Nantahala Capital Management, LLC | 5712702 | 17.6 |
| Perceptive Advisors LLC | 3074542 | 9.47 |
| Carlyle Group Inc. | 2857804 | 8.8 |
| Janus Henderson Group PLC | 2523897 | 7.78 |
| Adage Capital Partners GP L.L.C. | 1826814 | 5.63 |
| Vestal Point Capital, LP | 1300000 | 4 |
| Vanguard Group Inc | 969622 | 2.99 |
| Balyasny Asset Management LLC | 926876 | 2.86 |
| Avoro Capital Advisors LLC | 785000 | 2.42 |
| ETF | Compartilhar, % | Rentabilidade para o ano, % | Dividendos, % |
|---|---|---|---|
iShares Russell 2000 Growth ETF
|
0.08818 | 38.04 | 0.6026 |
| iShares ESG Aware MSCI USA Small-Cap ETF | 0.04862 | 18.09 | 1.49366 |
| iShares Morningstar Small-Cap Growth ETF | 0.04077 | 587.89 | 0.72598 |
| iShares Morningstar Small-Cap Growth ETF | 0.04077 | 33.63 | 0.72598 |
| iShares Morningstar Small-Cap ETF | 0.02055 | 391.25 | 1.60498 |
| iShares Morningstar Small-Cap ETF | 0.02055 | 30.1 | 1.60498 |
| iShares Russell 3000 ETF | 0.00204 | 24.83 | 1.43482 |
| 0.04 | 160.55 | 1.17 |
| Supervisor | Cargo | Pagamento | Ano de nascimento |
|---|---|---|---|
| Dr. Anish Bhatnagar M.D. | President, CEO, COO & Director | 1.06M | 1970 (55 anos) |
| Mr. James H. MacKaness | Chief Financial Officer | 640k | 1964 (61 ano) |
| Dr. Neil M. Cowen M.B.A., Ph.D. | Senior Vice President of Drug Development | N/A | |
| Ms. Kristen Yen M.S. | Senior Vice President of Clinical Operations | 317.19k | 1969 (56 anos) |
| Ms. Meredith Manning M.B.A. | Chief Commercial Officer | N/A | 1972 (53 ano) |
| Ms. Patricia C. Hirano M.P.H. | Senior Vice President of Regulatory Affairs | 493k | 1966 (59 anos) |
| Ms. Lauren Budesheim | Vice President of People | N/A | |
| Dr. Michael Huang M.D. | Senior Vice President of Clinical Development | N/A | 1974 (51 ano) |
| Dr. Raymond W. Urbanski M.D., Ph.D. | Chief Development Officer | 1959 (66 anos) |
Endereço: United States, Redwood City. CA, 203 Redwood Shores Parkway - abrir no Google Maps, abrir mapas Yandex
Site: https://soleno.life
Site: https://soleno.life
